BriaCell Therapeutics
BCTX
19 hedge funds and large institutions have $1.64M invested in BriaCell Therapeutics in 2026 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
1.19% less ownership
Funds ownership: 5.59% → 4.4% (-1.2%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
69% less capital inflows, than outflows
Capital inflows: $152K | Capital outflows: $499K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tripletail Wealth Management
Orlando,
Florida
|
+$111K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$38.6K |
| 3 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$1.36K |
| 4 |
HRT Financial
New York
|
+$1.27K |
| 5 |
Provenance Wealth Advisors
Fort Lauderdale,
Florida
|
+$126 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$262K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$160K |
| 3 |
LuminArx Capital Management
New York
|
-$55.5K |
| 4 |
Jane Street
New York
|
-$17.7K |
| 5 |
Morgan Stanley
New York
|
-$2.27K |
BCTX Hedge Fund Activity: Q3 2026 in Review
19 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in BriaCell Therapeutics (BCTX) for Q3 2026, worth a combined $1.64M — up 3.8% from $1.58M a quarter earlier.
Fund positioning in BCTX was balanced in Q3 2026: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was Tripletail Wealth Management, opening a new position worth an estimated $111K. The largest seller was Sabby Management, exiting entirely with an estimated $262K sold.
- 19 institutional investors held BriaCell Therapeutics (BCTX) as of Q3 2026, unchanged from Q2 2026.
- Funds reported $1.64M of BriaCell Therapeutics stock for Q3 2026, up 3.8% quarter-over-quarter.
- 4 funds opened new BriaCell Therapeutics positions in Q3 2026 and 4 closed out, a net change of 0 holders.
- The largest BriaCell Therapeutics buyer in Q3 2026 was Tripletail Wealth Management, an estimated $111K added.
- The largest BriaCell Therapeutics seller in Q3 2026 was Sabby Management, an estimated $262K sold.
Based on aggregated 13F filings for Q3 2026.